Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal von Ott, P.A., Piha-Paul, S.A., Munster, P., Pishvaian, M.J., van Brummelen, E.M.J., Cohen, R.B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., Simonelli, M., Morosky, A., Saraf, S., Emancipator, K., Koshiji, M., Bennouna, J.

Volltext

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study von Lee, Michael S, Ryoo, Baek-Yeol, Hsu, Chih-Hung, Numata, Kazushi, Stein, Stacey, Verret, Wendy, Hack, Stephen P, Spahn, Jessica, Liu, Bo, Abdullah, Heba, Wang, Yulei, He, Aiwu Ruth, Lee, Kyung-Hun, Bang, Y-J, Bendell, J, Chao, Y, Chen, J-S, Chung, H C, Davis, S L, Dev, A, Gane, E, George, B, He, A R, Hochster, H, Hsu, C-H, Ikeda, M, Lee, J, Lee, M, Mahipal, A, Manji, G, Morimoto, M, Numata, K, Pishvaian, M, Qin, S, Ryan, D, Ryoo, B-Y, Sasahira, N, Stein, S, Strickler, J, Tebbutt, N

Volltext

Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC) von Pishvaian, M.J., Lee, M.S., Ryoo, B.-Y., Stein, S., Lee, K.-H., Verret, W., Spahn, J., Shao, H., Liu, B., Iizuka, K., Hsu, C.-H.

Volltext

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study von Pishvaian, M.J., Weiss, G.J., Falchook, G.S., Yee, N., Gil-Martin, M., Shahda, S., Moreno, V., Brana, I., Crittenden, M., Formenti, S., Al-Rajabi, R., Papadopoulos, K.P., Stankevich, E., Feng, M., Li, J., Mathias, M., Kroog, G., Lowy, I., Fury, M.G.

Volltext

Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer von Shivapurkar, N., Mikhail, S., Navarro, R., Bai, W., Marshall, J., Hwang, J., Pishvaian, M., Wellstein, A., He, A. R.

Volltext

Disruption of transforming growth factor-β signaling through β-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation von KITISIN, K, GANESAN, N, MENDELSON, J, ZASLOFF, M, RASHID, A, FISHBEIN, T, EVANS, S. R. T, SIDAWY, A, REDDY, E. P, MISHRA, B, JOHNSON, L. B, SHETTY, K, TANG, Y, MISHRA, L, JOGUNOORI, W, VOLPE, E. A, KIM, S. S, KATURI, V, KALLAKURY, B, PISHVAIAN, M, ALBANESE, C

Volltext

Cadherin-11 is expressed in invasive breast cancer cell lines von PISHVAIAN, M. J, FELTES, C. M, THOMPSON, P, BUSSEMAKERS, M. J, SCHALKEN, J. A, BYERS, S. W

Volltext

A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer (vol 124, pg 2337, 2018) von Pishvaian, M. J., Slack, R. S., Jiang, W.

Volltext

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial (vol 2... von Pishvaian, M. J., Blais, E. M., Brody, J. R.

Volltext

LBA-1 The Phase III Study: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-pa... von Pishvaian, M., Lopez, C., Zervos, E., Hatoum, H., Berg, D., Ucar, A., Boone, B., Johnson, T., Zureikat, A., Kenneth, M., Chung, K., Gandhi, R., Nazemzadeh, R., Parikh, N., Novelli, P., Kouri, B., Laing, C., Bates, S., Agah, R., Goodman, K.

Volltext

1437TiP Phase Ib/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable o... von Park, H., Bekaii-Saab, T., Kim, S., Kamath, S., Pishvaian, M., Ford, J., Zhen, D., Mayor, J., Lux, C., Tan, Q., Strickler, J.

Volltext

492TiP A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion von Johnson, M.L., Rodon, J., Aljumaily, R., Villalona-Calero, M., Borazanci, E., Pishvaian, M., Turk, A., Carvajal, R.D., Mantia, C., Giaccone, G., Mounir, Z., Patel, A., Maurer, M., Neilan, C., Rajendran, D., Ganesan, U., Hinkle, J., Tolcher, A.W.

Volltext

LBA26Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC) von Pishvaian, M J, Lee, M S, Ryoo, B-Y, Stein, S, Lee, K-H, Verret, W, Spahn, J, Shao, H, Liu, B, Iizuka, K, Hsu, C-H

Volltext

Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours von Naing, A., Bauer, T., Papadopoulos, K.P., Rahma, O., Tsai, F., Garralda, E., Naidoo, J., Pai, S., Gibson, M.K., Rybkin, I., Wang, D., McDermott, D.F., Fasolo, A., de Miguel, M., Shaheen, M., Jenkins, Y., Kallender, H., Gogov, S., Kuriakose, E., Pishvaian, M.

Volltext

440O - Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumour... von Naing, A., Bauer, T., Papadopoulos, K.P., Rahma, O., Tsai, F., Garralda, E., Naidoo, J., Pai, S., Gibson, M.K., Rybkin, I., Wang, D., McDermott, D.F., Fasolo, A., de Miguel, M., Shaheen, M., Jenkins, Y., Kallender, H., Gogov, S., Kuriakose, E., Pishvaian, M.

Volltext

Cross-regulation of β-catenin–LEF/TCF and retinoid signaling pathways von Easwaran, Vijayasurian, Pishvaian, Michael, Salimuddin, Byers, Stephen

Volltext

440OPhase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours von Naing, A, Bauer, T, Papadopoulos, K P, Rahma, O, Tsai, F, Garralda, E, Naidoo, J, Pai, S, Gibson, M K, Rybkin, I, Wang, D, McDermott, D F, Fasolo, A, de Miguel, M, Shaheen, M, Jenkins, Y, Kallender, H, Gogov, S, Kuriakose, E, Pishvaian, M

Volltext

73PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study von He, A R, Weiss, G J, Falchook, G, Yee, N S, Gil-Martin, M, Shahda, S, Moreno, V, Brana, I, Crittenden, M, Formenti, S, Al-Rajabi, R, Papadopoulos, K P, Pishvaian, M J, Stankevich, E, Feng, M, Li, J, Mathias, M, Kroog, G, Lowy, I, Fury, M G

Volltext

1151PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study von Pishvaian, M J, Weiss, G J, Falchook, G S, Yee, N, Gil-Martin, M, Shahda, S, Moreno, V, Brana, I, Crittenden, M, Formenti, S, Al-Rajabi, R, Papadopoulos, K P, Stankevich, E, Feng, M, Li, J, Mathias, M, Kroog, G, Lowy, I, Fury, M G

Volltext

Comparative molecular analyses of pancreatic cancer (PC): Younger vs. older patients (pts) von Salem, M., Philip, P., Feldman, R., Hwang, J., Pishvaian, M., Xiu, J., Eldeiry, W., Reddy, S., Gatalica, Z., Trivedi, N., Zareb, A., Colton, B.S., Wang, H., Shields, A., Marshall, J.

Volltext